Abstract
Hodgkin’s and non-Hodgkin’s lymphomas are lymphoid neoplasms arising from B cells, T cells, or NK (natural killer) cells. [18F]FDG PET/CT is more accurate for the primary staging of lymphoma particularly because it can detect disease in normal sized lymph nodes, the liver, spleen and bone marrow. A major advantage of [18F]FDG PET in determining the outcome of therapy is distinguishing active lymphoma from fibrosis/necrosis in residual masses. Posttherapy [18F]FDG PET provides important prognostic information and has been incorporated into the currently used criteria for evaluating response to therapy in lymphoma (revised International Workshop Criteria—IWC). Interim [18F]FDG PET/CT also provides prognostic information and is being evaluated for “risk-adapted therapy” in setting of clinical trials. Radioimmunotherapy with the anti-CD20 monoclonal antibodies, 90 Y-ibritumomab and 131 I-tositumomab, is effective therapy for non-Hodgkin’s lymphoma. Currently, radioimmunotherapy is used in the relapsed/refractory setting and also for consolidation after front-line chemotherapy in low-grade follicular lymphoma. Optimal usage of radioimmunotherapy and additional indications are areas of ongoing active investigations.
Original language | English (US) |
---|---|
Title of host publication | Nuclear Oncology |
Subtitle of host publication | Pathophysiology and Clinical Applications |
Publisher | Springer New York |
Pages | 153-187 |
Number of pages | 35 |
ISBN (Electronic) | 9780387488943 |
ISBN (Print) | 9780387488936 |
DOIs | |
State | Published - Jan 1 2013 |
Externally published | Yes |
Keywords
- Hodgkin’s lymphoma
- Lymphomas and [<sup>18</sup>F]FDG PET/CT
- Non-Hodgkin’s lymphoma
- Radioimmunotherapy in lymphomas
- [<sup>18</sup>F]FDG PET and lymphomas
ASJC Scopus subject areas
- General Medicine